5-(3,4-Dimethoxyphenyl)-2-thiophen-2-yl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 5-(3,4-Dimethoxyphenyl)-2-thiophen-2-yl-7-(trifluoromethyl)pyrazolo[1,5-a]pyrimidine
• 化学式: C₁₉H₁₄F₃N₃O₂S
• 分子量: 405.4
• InChiKey: CLFOYJSEPPNFQZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.2
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  76.9
• 氢给体数：
  0
• 氢受体数：
  8

文献信息

• USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3775208A1

  公开（公告）日：2021-02-17
• [EN] USE OF FUBP1 INHIBITORS FOR TREATING HEPATITIS B VIRUS INFECTION<br/>[FR] UTILISATION D'INHIBITEURS DE FUBP1 DANS LE TRAITEMENT D'UNE INFECTION PAR LE VIRUS DE L'HÉPATITE B
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019193165A1

  公开（公告）日：2019-10-10

  The present invention relates to a FUBP1 inhibitor for use in treatment of an HBV infection, in particular a chronic HBV infection. The invention in particular relates to the use of FUBP1 inhibitors for destabilizing cccDNA, such as HBV cccDNA. The invention also relates to nucleic acid molecules, such as oligonucleotides including siRNA, shRNA and antisense oligonucleotides, which are complementary to FUBP1 and capable of reducing a FUBP1 mRNA. Also comprised in the present invention is a pharmaceutical composition and its use in the treatment and/or prevention of a HBV infection.